China Pharma Holdings (CPHI) Free Cash Flow (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Free Cash Flow came in at -$55292.0 in Q1 2026, up 58.11% YoY from -$34970.1 in Q1 2025, and down 136.49% on a QoQ basis from $151536.0 in Q4 2025.
China Pharma Holdings (CPHI) Free Cash Flow (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Free Cash Flow data on file, last reported at -$55292.0 in Q1 2026.
- Quarterly Free Cash Flow rose 58.11% year-over-year to -$55292.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165645.0 (up 350.49% YoY) and the FY2025 annual result came in at $88937.0, up 120.01% from the prior year.
- Free Cash Flow declined to -$55292.0 in Q1 2026, from $151536.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $939831.0 in Q3 2023 to a low of -$1.4 million in Q1 2023.
- A 5-year average of -$112085.6 and a median of -$55292.0 in 2026 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow surged 2911.59% — and 2025, when it sank 529.7%.
- Tracing CPHI's Free Cash Flow over 5 years: stood at $611862.0 in 2022, then slumped by 104.39% to -$26850.0 in 2023, then jumped by 1139.96% to $279228.0 in 2024, then sank by 45.73% to $151536.0 in 2025, then tumbled by 136.49% to -$55292.0 in 2026.
- The last three Free Cash Flow figures came in at -$55292.0 (Q1 2026), $151536.0 (Q4 2025), and -$237598.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | China Pharma Holdings | 42.13 Mn | 41.82 Mn | 83,566.00 | -32,828.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55,292.00 |
| Mar 31, 2026 | -55,292.00 |
| Dec 31, 2025 | 151,536.00 |
| Dec 31, 2025 | 151,536.00 |
| Sep 30, 2025 | -237,598.00 |
| Sep 30, 2025 | -237,598.00 |
| Jun 30, 2025 | 306,999.00 |
| Jun 30, 2025 | 306,999.00 |
| Mar 31, 2025 | -132,000.00 |
| Mar 31, 2025 | -132,000.00 |
| Dec 31, 2024 | 279,228.00 |
| Dec 31, 2024 | 279,228.00 |
| Sep 30, 2024 | -37,732.00 |
| Sep 30, 2024 | -37,732.00 |
| Jun 30, 2024 | -72,726.00 |
| Jun 30, 2024 | -72,726.00 |
| Mar 31, 2024 | -585,158.00 |
| Mar 31, 2024 | -585,158.00 |
| Dec 31, 2023 | -26,850.00 |
| Dec 31, 2023 | -26,850.00 |